Responses
Clinical/translational cancer immunotherapy
Original research
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
